



Medicines & Healthcare products  
Regulatory Agency



**MHRA**

10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

Prof C Butler  
UNIVERSITY OF OXFORD  
NUFFIELD DEPARTMENT OF PRIMARY CARE HEALTH SCIENCES,  
RADCLIFFE OBSERVATORY QUARTER, WOODSTOCK ROAD  
OXFORD  
OX2 6GG  
UNITED KINGDOM

26/03/2020

Dear Prof C Butler,

**THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031**

Our Reference:	CTA 21584/0426/001-0001
Eudract Number:	2020-001209-22
Product:	Plaquenil-Hydroxychloroquine
Protocol number:	PRINCIPLE

**NOTICE OF ACCEPTANCE**

I am writing to inform you that the Licensing Authority accepts your request for a clinical trial authorisation (CTA), received on 24/03/2020.

The authorisation is effective from the date of this letter although your trial may be suspended or terminated at any time by the Licensing Authority in accordance with regulation 31. You must notify the Licensing Authority within 90 days of the trial ending.

Finally, you are reminded that a favourable opinion from the Ethics Committee is also required before this trial can proceed.

Yours sincerely,

**Clinical Trials Unit  
MHRA**